Senti Biosciences HoldingsSNTI +3.00%22 Quick Ratio is 1.04 as of Mar. 2026, which is 80% below its 10-year median of 5.26. GuruFocus rates SNTI with a GF Score™ of 22/100. The stock has 7 warning signs investors should review. Among 1,411 Biotechnology companies, Senti Biosciences Holdings ranks worse than 79.8% on this metric.
Senti Biosciences Holdings has a quick ratio of 1.04. It generally indicates good short-term financial strength.
The historical rank and industry rank for Senti Biosciences Holdings's Quick Ratio or its related term are showing as below:
SNTI'
s Quick Ratio Range Over the Past 10 Years
Min: 1.04 Med: 5.26 Max: 8.09
Current: 1.04
During the past 6 years, Senti Biosciences Holdings's highest Quick Ratio was 8.09. The lowest was 1.04. And the median was 5.26.
SNTI's Quick Ratio is ranked worse than 79.8% of 1411
companies
in the Biotechnology industry
Industry Median: 3.59
vs SNTI: 1.04
Senti Biosciences Holdings (NAS:SNTI) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Senti Biosciences Holdings Quick Ratio Related Terms
Senti Biosciences Holdings Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Senti Biosciences Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senti Biosciences Holdings Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Senti Biosciences Holdings's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Senti Biosciences Holdings's Quick Ratio falls into.
Senti Biosciences Holdings Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senti Biosciences Holdings (SNTI) has a Quick Ratio of 1.04 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Senti Biosciences Holdings and its competitors. This is 80% below median its historical median of 5.26. Over the past decade, Senti Biosciences Holdings' Quick Ratio has ranged from 1.04 to 8.09. According to the industry distribution chart, Senti Biosciences Holdings ranks #1126 out of 1411 companies in the Biotechnology industry, placing it in the top 79.8%.
Is Senti Biosciences Holdings' Quick Ratio too high?
Senti Biosciences Holdings' current Quick Ratio of 1.04 is 80% below median its 10-year median of 5.26. Over the past 10 years, this metric has ranged from a low of 1.04 to a high of 8.09. The Biotechnology industry median Quick Ratio is 3.59. Senti Biosciences Holdings' value of 1.04 is 71% below this industry median. Based on the distribution chart, Senti Biosciences Holdings ranks #1126 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Senti Biosciences Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Senti Biosciences Holdings' Quick Ratio compare to ALGS and CRVO?
According to the Biotechnology industry distribution chart, Senti Biosciences Holdings ranks #1126 out of 1411 companies for Quick Ratio. This places Senti Biosciences Holdings in the lower half of its industry. The industry median Quick Ratio is 3.59. Senti Biosciences Holdings' value of 1.04 is 71% below this benchmark. Historically, Senti Biosciences Holdings' own Quick Ratio has ranged from 1.04 to 8.09 over the past decade. While the company's 10-year median is 5.26 vs. the industry median of 3.59, Senti Biosciences Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Senti Biosciences Holdings's current Quick Ratio of 1.04 is 71% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Senti Biosciences Holdings and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senti Biosciences Holdings's current Quick Ratio is 1.04, which is 80% below median its own 10-year median of 5.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senti Biosciences Holdings stock overvalued right now?
Senti Biosciences Holdings (SNTI) has a current Quick Ratio of 1.04. The current Quick Ratio is 1.04, which is 80% below median its 10-year median of 5.26 and 71% below the Biotechnology industry median of 3.59. Senti Biosciences Holdings' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Senti Biosciences Holdings (SNTI), the current Quick Ratio is 1.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
22GF Score
Get the complete analysis for SNTI
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNTI has been successfully added to your 
